Jazz Pharmaceuticals plc G50871105 IE00B4Q5ZN47 07/24/2025 To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals pic's named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 1750.000000 0 FOR 1750.000000 FOR Replimune Group, Inc. 76029N106 US76029N1063 09/03/2025 To approve, on a non-binding advisory basis, the compensation of Replimune Group, Inc.'s named executive officers for the fiscal year ended March 31, 2025. SECTION 14A SAY-ON-PAY VOTES 47300.000000 0 FOR 47300.000000 FOR Roivant Sciences Ltd. G76279101 BMG762791017 09/10/2025 To cast a non-binding, advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 39000.000000 0 AGAINST 39000.000000 AGAINST IQVIA Holdings Inc. 46266C105 US46266C1053 04/23/2026 Approve an advisory (non-binding) resolution to approve IQVIA's executive compensation (say-on-pay). SECTION 14A SAY-ON-PAY VOTES 6000.000000 0 FOR 6000.000000 FOR Johnson & Johnson 478160104 US4781601046 04/23/2026 Advisory Vote to Approve Named Executive Officer Compensation SECTION 14A SAY-ON-PAY VOTES 14700.000000 0 FOR 14700.000000 FOR Pfizer Inc. 717081103 US7170811035 04/23/2026 2026 advisory approval of executive compensation SECTION 14A SAY-ON-PAY VOTES 27150.000000 0 FOR 27150.000000 FOR Abbott Laboratories 002824100 US0028241000 04/24/2026 Say on Pay - An Advisory Vote on the Approval of Executive Compensation SECTION 14A SAY-ON-PAY VOTES 23498.000000 0 FOR 23498.000000 FOR Boston Scientific Corporation 101137107 US1011371077 04/30/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 34626.000000 0 FOR 34626.000000 FOR Gilead Sciences, Inc. 375558103 US3755581036 04/30/2026 To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 15990.000000 0 FOR 15990.000000 FOR Inspire Medical Systems, Inc. 457730109 US4577301090 04/30/2026 Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 7200.000000 0 FOR 7200.000000 FOR Inspire Medical Systems, Inc. 457730109 US4577301090 04/30/2026 Approval, on a advisory (non-binding) basis, of the frequency of future advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 7200.000000 0 ONE YEAR 7200.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 04/30/2026 To approve, by advisory vote, the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES 5250.000000 0 FOR 5250.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/04/2026 Approval, on an advisory basis, of the compensation paid to the company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 5551.000000 0 FOR 5551.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/05/2026 Advisory Vote to Approve the Compensation of our Named Executive Officers SECTION 14A SAY-ON-PAY VOTES 21000.000000 0 FOR 21000.000000 FOR Danaher Corporation 235851102 US2358511028 05/05/2026 To approve on an advisory basis the Company's named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 9575.000000 0 FOR 9575.000000 FOR Moderna, Inc. 60770K107 US60770K1079 05/06/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 4350.000000 0 AGAINST 4350.000000 AGAINST Moderna, Inc. 60770K107 US60770K1079 05/06/2026 To approve, on a non-binding, advisory basis, the frequency of future non-binding advisory votes to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 4350.000000 0 ONE YEAR 4350.000000 FOR Stryker Corporation 863667101 US8636671013 05/06/2026 Advisory Vote to Approve Named Executive Officer Compensation. SECTION 14A SAY-ON-PAY VOTES 5850.000000 0 FOR 5850.000000 FOR Edwards Lifesciences Corporation 28176E108 US28176E1082 05/07/2026 Advisory Vote to Approve Named Executive Officer Compensation SECTION 14A SAY-ON-PAY VOTES 17250.000000 0 FOR 17250.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/08/2026 Say on Pay - An advisory vote on the approval of executive compensation SECTION 14A SAY-ON-PAY VOTES 12200.000000 0 FOR 12200.000000 FOR Abivax SA 00370M103 US00370M1036 05/11/2026 Approve Compensation of Sylvie Gregoire, Chairwoman of the Board SECTION 14A SAY-ON-PAY VOTES 2340.000000 0 AGAINST 2340.000000 AGAINST Abivax SA 00370M103 US00370M1036 05/11/2026 Approve Compensation of Marc de Garidel, CEO SECTION 14A SAY-ON-PAY VOTES 2340.000000 0 AGAINST 2340.000000 AGAINST Insmed Incorporated 457669307 US4576693075 05/13/2026 An advisory vote on the 2025 compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 16150.000000 0 FOR 16150.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/13/2026 Advisory vote to approve named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 7607.000000 0 FOR 7607.000000 FOR Medpace Holdings, Inc. 58506Q109 US58506Q1094 05/15/2026 To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2026 Annual Meeting. SECTION 14A SAY-ON-PAY VOTES 430.000000 0 FOR 430.000000 FOR Medpace Holdings, Inc. 58506Q109 US58506Q1094 05/15/2026 To recommend, on an advisory basis, the frequency of future advisory votes on named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 430.000000 0 ONE YEAR 430.000000 FOR Amgen Inc. 031162100 US0311621009 05/19/2026 Advisory vote to approve our executive compensation. SECTION 14A SAY-ON-PAY VOTES 10030.000000 0 FOR 10030.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/20/2026 To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers. SECTION 14A SAY-ON-PAY VOTES 2310.000000 0 FOR 2310.000000 FOR Privia Health Group, Inc. 74276R102 US74276R1023 05/20/2026 To approve, on an advisory (non-binding) basis, the compensation of our named executive officers ("NEOs"). SECTION 14A SAY-ON-PAY VOTES 26970.000000 0 FOR 26970.000000 FOR Thermo Fisher Scientific Inc. 883556102 US8835561023 05/20/2026 An advisory vote to approve named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 3500.000000 0 AGAINST 3500.000000 AGAINST Illumina, Inc. 452327109 US4523271090 05/21/2026 To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 2132.000000 0 FOR 2132.000000 FOR Tempus AI, Inc. 88023B103 US88023B1035 05/21/2026 To consider a non-binding advisory vote on the frequency of future stockholder votes to approve the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 3880.000000 0 ONE YEAR 3880.000000 AGAINST Vera Therapeutics, Inc. 92337R101 US92337R1014 05/21/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 25502.000000 0 FOR 25502.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/26/2026 Non-binding advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 21400.000000 0 FOR 21400.000000 FOR Cytokinetics, Incorporated 23282W605 US23282W6057 05/27/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 7300.000000 0 FOR 7300.000000 FOR DexCom, Inc. 252131107 US2521311074 05/27/2026 To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2025. SECTION 14A SAY-ON-PAY VOTES 23100.000000 0 FOR 23100.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/27/2026 Advisory vote on the compensation paid to the Company's named executive officers; SECTION 14A SAY-ON-PAY VOTES 2300.000000 0 FOR 2300.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/01/2026 Advisory approval of the Company's executive compensation. SECTION 14A SAY-ON-PAY VOTES 14895.000000 0 FOR 14895.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 06/02/2026 To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 9450.000000 0 FOR 9450.000000 FOR PTC Therapeutics, Inc. 69366J200 US69366J2006 06/02/2026 Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 6650.000000 0 FOR 6650.000000 FOR RadNet, Inc. 750491102 US7504911022 06/02/2026 An advisory vote to approve the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES 7970.000000 0 FOR 7970.000000 FOR Trevi Therapeutics, Inc. 89532M101 US89532M1018 06/03/2026 Approval, on an advisory basis, of the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES 74290.000000 0 FOR 74290.000000 FOR Alignment Healthcare, Inc. 01625V104 US01625V1044 06/04/2026 Approval, on an non-binding, advisory basis, of the compensation of our Named Executive Officers SECTION 14A SAY-ON-PAY VOTES 26785.000000 0 FOR 26785.000000 FOR Ionis Pharmaceuticals, Inc. 462222100 US4622221004 06/04/2026 To make an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES 7200.000000 0 FOR 7200.000000 FOR Kura Oncology, Inc. 50127T109 US50127T1097 06/04/2026 Approval, on an advisory basis, of the compensation of our named executive officers ("Say-on-Pay"), as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 71350.000000 0 FOR 71350.000000 FOR Kura Oncology, Inc. 50127T109 US50127T1097 06/04/2026 Indication, on an advisory basis, of the preferred frequency of holding future Say-on-Pay votes on executive compensation. SECTION 14A SAY-ON-PAY VOTES 71350.000000 0 ONE YEAR 71350.000000 FOR Nektar Therapeutics 640268306 US6402683063 06/04/2026 To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote). SECTION 14A SAY-ON-PAY VOTES 10827.000000 0 FOR 10827.000000 FOR Royalty Pharma plc G7709Q104 GB00BMVP7Y09 06/04/2026 A non-binding advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES 7200.000000 0 FOR 7200.000000 FOR Axsome Therapeutics, Inc. 05464T104 US05464T1043 06/05/2026 To approve, by non-binding advisory vote, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 1500.000000 0 FOR 1500.000000 FOR Incyte Corporation 45337C102 US45337C1027 06/08/2026 Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 2350.000000 0 FOR 2350.000000 FOR Tectonic Therapeutic, Inc. 878972108 US8789721086 06/08/2026 Advisory approval of the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES 24000.000000 0 FOR 24000.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/09/2026 Say on Pay - To hold an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES 1850.000000 0 FOR 1850.000000 FOR Cogent Biosciences, Inc. 19240Q201 US19240Q2012 06/09/2026 Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 26700.000000 0 FOR 26700.000000 FOR Palisade Bio, Inc. 696389402 US6963894026 06/10/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 88000.000000 0 AGAINST 88000.000000 AGAINST Summit Therapeutics Inc. 86627T108 US86627T1088 06/10/2026 Approval, by a non-binding advisory vote, of the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 69500.000000 0 AGAINST 69500.000000 AGAINST Syndax Pharmaceuticals, Inc. 87164F105 US87164F1057 06/10/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 proxy statement. SECTION 14A SAY-ON-PAY VOTES 31600.000000 0 FOR 31600.000000 FOR uniQure N.V. N90064101 NL0010696654 06/10/2026 Approval, on an advisory basis, of the compensation of the named executive officers of the Company. SECTION 14A SAY-ON-PAY VOTES 29100.000000 0 FOR 29100.000000 FOR uniQure N.V. N90064101 NL0010696654 06/10/2026 Approval, on an advisory basis, of the frequency of advisory votes on the compensation of the named executive officers of the Company. SECTION 14A SAY-ON-PAY VOTES 29100.000000 0 ONE YEAR 29100.000000 FOR Arcus Biosciences, Inc. 03969F109 US03969F1093 06/11/2026 To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 45000.000000 0 FOR 45000.000000 FOR BeOne Medicines Ltd. 06/11/2026 THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, for the fiscal year ended December 31, 2025 be and is hereby approved. SECTION 14A SAY-ON-PAY VOTES 44700.000000 0 FOR 44700.000000 FOR BeOne Medicines Ltd. 07725L102 US07725L1026 06/11/2026 THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, for the fiscal year ended December 31, 2025 be and is hereby approved. SECTION 14A SAY-ON-PAY VOTES 1870.000000 0 FOR 1870.000000 FOR Regeneron Pharmaceuticals, Inc. 75886F107 US75886F1075 06/12/2026 Proposal to approve, on an advisory basis, compensation of the Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES 2913.000000 0 FOR 2913.000000 FOR Ardelyx, Inc. 039697107 US0396971071 06/16/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the proxy statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"); SECTION 14A SAY-ON-PAY VOTES 122114.000000 0 FOR 122114.000000 FOR Ardelyx, Inc. 039697107 US0396971071 06/16/2026 To approve, on a non-binding, advisory basis, whether a Say-on-Pay vote should occur every one (1) year, every two (2) years or every three (3) years; SECTION 14A SAY-ON-PAY VOTES 122114.000000 0 ONE YEAR 122114.000000 FOR Guardant Health, Inc. 40131M109 US40131M1099 06/17/2026 Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 1980.000000 0 FOR 1980.000000 FOR Guardant Health, Inc. 40131M109 US40131M1099 06/17/2026 Non-binding advisory vote on the frequency of stockholder advisory votes regarding compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 1980.000000 0 ONE YEAR 1980.000000 FOR Madrigal Pharmaceuticals, Inc. 558868105 US5588681057 06/17/2026 Advisory vote to approve executive compensation SECTION 14A SAY-ON-PAY VOTES 305.000000 0 FOR 305.000000 FOR Structure Therapeutics Inc. 86366E106 US86366E1064 06/17/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 9650.000000 0 FOR 9650.000000 FOR ORIC Pharmaceuticals, Inc. 68622P109 US68622P1093 06/18/2026 To approve, on an advisory basis, executive compensation. SECTION 14A SAY-ON-PAY VOTES 23500.000000 0 FOR 23500.000000 FOR ORIC Pharmaceuticals, Inc. 68622P109 US68622P1093 06/18/2026 To approve, on an advisory basis, the frequency of future advisory votes on executive compensation. SECTION 14A SAY-ON-PAY VOTES 23500.000000 0 ONE YEAR 23500.000000 FOR Revolution Medicines, Inc. 76155X100 US76155X1000 06/18/2026 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"). SECTION 14A SAY-ON-PAY VOTES 1830.000000 0 FOR 1830.000000 FOR BridgeBio Pharma, Inc. 10806X102 US10806X1028 06/22/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 8100.000000 0 FOR 8100.000000 FOR BridgeBio Pharma, Inc. 10806X102 US10806X1028 06/22/2026 To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 8100.000000 0 ONE YEAR 8100.000000 FOR ARS Pharmaceuticals, Inc. 82835W108 US82835W1080 06/24/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement. SECTION 14A SAY-ON-PAY VOTES 79000.000000 0 AGAINST 79000.000000 AGAINST ARS Pharmaceuticals, Inc. 82835W108 US82835W1080 06/24/2026 To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 79000.000000 0 ONE YEAR 79000.000000 FOR Tarsus Pharmaceuticals, Inc. 87650L103 US87650L1035 06/25/2026 To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 13250.000000 0 FOR 13250.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2026 Advisory resolution to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES 1370.000000 0 FOR 1370.000000 FOR